We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Analyst Reports for Pfizer, TJX Companies & Honda
Read MoreHide Full Article
Thursday, August 17, 2017
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE - Free Report) , TJX Companies (TJX - Free Report) and Honda (HMC - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Pfizer shares have underperformed the peer group as well as the broader market over the past year (the stock is down -5.2% over the last year vs. a +1.7% increase for the Zacks Large-Cap Pharmaceuticals industry and the +12.5% gain for the S&P 500 index) on continued drug pricing uncertainty that have refused to go away even after the election.
Pfizer’s second-quarter results were mixed with earnings beating expectations even as sales came in lower than projected. The drugmaker continues to face headwinds in the form of genericization of key drugs, lost alliance revenues, pricing pressure and rising competition, which are hurting the top line.
But the Zacks analyst thinks that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential.
Shares of TJX Companies have underperformed the Zacks Discount Stores industry over the last one month, gaining +2.3% vs. +3.8%. The company’s second-quarter results exceeded expectations, driven by improved traffic and margin improvements, as well as higher market share. The company also raised its fiscal 2018 earnings guidance.
The Zacks analyst likes the company’s brand enhancing initiative, aggressive store opening strategy and improving e-commerce business. However, the company is facing disappointing comps growth of late. The company is also facing margin pressure due to higher payroll and pension related costs. Currency headwinds are another concern.
Strong Buy-rated Honda’s shares have lagged its auto peers over the last one year losing -7.5% vs. -5.1%. However, Honda reported better-than-expected earnings in the first quarter of fiscal 2018. Both earnings and revenues rose year over year too. The year-over-year increase can be attributed to higher revenues in financial services, motorcycle business operations and foreign currency conversion effects. Also, record-high production in the first-half of calendar year 2017 outside Japan is aiding Honda.
Moreover, the company has been focusing on infrastructural development, new product introductions and car launches in Asia, North and South America. Honda has also planned to launch fuel cell vehicles in U.S. and European markets. These efforts are expected to popularize the company and attract more customers, which in turn will boost the revenue figure. It is also undertaking frequent collaborations in order to expand its business.
Other noteworthy reports we are featuring today include American Electric (AEP - Free Report) , Pioneer Natural Resources (PXD - Free Report) and Novo Nordisk (NVO - Free Report) .
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today. Learn more >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Analyst Reports for Pfizer, TJX Companies & Honda
Thursday, August 17, 2017
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE - Free Report) , TJX Companies (TJX - Free Report) and Honda (HMC - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Pfizer shares have underperformed the peer group as well as the broader market over the past year (the stock is down -5.2% over the last year vs. a +1.7% increase for the Zacks Large-Cap Pharmaceuticals industry and the +12.5% gain for the S&P 500 index) on continued drug pricing uncertainty that have refused to go away even after the election.
Pfizer’s second-quarter results were mixed with earnings beating expectations even as sales came in lower than projected. The drugmaker continues to face headwinds in the form of genericization of key drugs, lost alliance revenues, pricing pressure and rising competition, which are hurting the top line.
But the Zacks analyst thinks that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential.
(You can read the full research report on Pfizer here >>>).
Shares of TJX Companies have underperformed the Zacks Discount Stores industry over the last one month, gaining +2.3% vs. +3.8%. The company’s second-quarter results exceeded expectations, driven by improved traffic and margin improvements, as well as higher market share. The company also raised its fiscal 2018 earnings guidance.
The Zacks analyst likes the company’s brand enhancing initiative, aggressive store opening strategy and improving e-commerce business. However, the company is facing disappointing comps growth of late. The company is also facing margin pressure due to higher payroll and pension related costs. Currency headwinds are another concern.
(You can read the full research report on TJX Companies here >>>).
Strong Buy-rated Honda’s shares have lagged its auto peers over the last one year losing -7.5% vs. -5.1%. However, Honda reported better-than-expected earnings in the first quarter of fiscal 2018. Both earnings and revenues rose year over year too. The year-over-year increase can be attributed to higher revenues in financial services, motorcycle business operations and foreign currency conversion effects. Also, record-high production in the first-half of calendar year 2017 outside Japan is aiding Honda.
Moreover, the company has been focusing on infrastructural development, new product introductions and car launches in Asia, North and South America. Honda has also planned to launch fuel cell vehicles in U.S. and European markets. These efforts are expected to popularize the company and attract more customers, which in turn will boost the revenue figure. It is also undertaking frequent collaborations in order to expand its business.
(You can read the full research report on Honda here >>>).
Other noteworthy reports we are featuring today include American Electric (AEP - Free Report) , Pioneer Natural Resources (PXD - Free Report) and Novo Nordisk (NVO - Free Report) .
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today. Learn more >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>